{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:41:37Z","timestamp":1779313297611,"version":"3.51.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The objective of this research is to scrutinize adverse events (AEs) linked to Trifluridine\/Tipiracil (TFTD\/TPI), using data from the FDA Adverse Event Reporting System (FAERS) database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The AEs data related to TFTD\/TPI were collected from the fourth quarter of 2015 through the fourth quarter of 2023. After normalizing the data, multiple signal quantification techniques including Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Bayesian approaches such as Bayesian Confidence Propagation Neural Network (BCPNN) and the Multi-item Gamma Poisson Shrinker (MGPS) were used for overall and subgroup analysis and visualization analyses were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From the FAERS database, we analyzed 13,520,073 reports, identifying 8,331 as primary suspect (PS) AEs for TFTD\/TPI, occurring across 27 organ systems. The study retained 99 significant disproportionality Preferred Terms (PTs) across four algorithms and unveiled unexpected serious AEs such as iron deficiency and intestinal perforation, hepatic failure, cholangitis and so on. The median onset of TFTD\/TPI-associated AEs was 44\u00a0days (IQR 20-97 days), with most occurring within the first 30 days of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This research uncovers critical new safety signals for TFTD\/TPI, supporting its clinical monitoring and risk identification.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1399998","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T08:58:09Z","timestamp":1721725089000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Signal mining and analysis of trifluridine\/tipiracil adverse events based on real-world data from the FAERS database"],"prefix":"10.3389","volume":"15","author":[{"given":"Yongli","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhisheng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenglou","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianxiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxu","family":"Da","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e000698","DOI":"10.1136\/esmoopen-2020-000698","article-title":"Safety, efficacy and patient-reported outcomes with trifluridine\/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study","volume":"5","author":"Bachet","year":"2020","journal-title":"ESMO Open"},{"key":"B2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1176950","DOI":"10.3389\/fonc.2023.1176950","article-title":"Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements","volume":"13","author":"Cann","year":"2023","journal-title":"Front. Oncol."},{"key":"B4","first-page":"21","article-title":"TAS-102 an emerging oral fluoropyrimidine","volume":"36","author":"Chen","year":"2016","journal-title":"Anticancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3322\/caac.21728","article-title":"Clinical management of metastatic colorectal cancer in the era of precision medicine","volume":"72","author":"Ciardiello","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.3390\/cancers15133465","article-title":"Tas-102 for refractory metastatic colorectal cancer: a multicenter retrospective cohort study","volume":"15","author":"Conti","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.5414\/CP204410","article-title":"Analysis of neutropenia as a predictive factor of the efficacy of trifluridine-tipiracil treatment","volume":"61","author":"Dom\u00ednguez sen\u00edn","year":"2023","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40264-023-01391-4","article-title":"Enhancing transparency in defining studied drugs: the open-source living DiAna dictionary for standardizing drug names in the FAERS","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B9","doi-asserted-by":"publisher","first-page":"102218","DOI":"10.1016\/j.ctrv.2021.102218","article-title":"Metastatic colorectal cancer: advances in the folate-fluoropyrimidine chemotherapy backbone","volume":"98","author":"Glimelius","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s12094-023-03268-5","article-title":"Efficacy and safety of trifluridine\/tipiracil (TAS-102) in patients with metastatic colorectal cancer: a systematic review and meta-analysis","volume":"26","author":"Huang","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database","volume":"346","author":"Jiang","year":"2024","journal-title":"J. Affect Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"101614","DOI":"10.1016\/j.esmoop.2023.101614","article-title":"Real-world evidence of trifluridine\/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan","volume":"8","author":"Kagawa","year":"2023","journal-title":"ESMO Open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1093\/oncolo\/oyad296","article-title":"Trifluridine\/tipiracil plus bevacizumab for vulnerable patients with pretreated metastatic colorectal cancer: a retrospective study (WJOG14520G)","volume":"29","author":"Kito","year":"2024","journal-title":"Oncologist"},{"key":"B14","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019","volume":"8","author":"Kocarnik","year":"2022","journal-title":"JAMA Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/ijc.34603","article-title":"Effectiveness, safety and quality of life of trifluridine\/tipiracil in pretreated patients with metastatic colorectal cancer: real-world data from the noninterventional TACTIC study in Germany","volume":"153","author":"Kr\u00f6ning","year":"2023","journal-title":"Int. J. Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1038\/s41416-023-02212-2","article-title":"Trifluridine\/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial","volume":"128","author":"Kuboki","year":"2024","journal-title":"Br. J. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.tjog.2020.03.007","article-title":"Bevacizumab-related gastrointestinal perforation in patients with three or more prior chemotherapy regimens: a real-world experience","volume":"59","author":"Matsumiya","year":"2020","journal-title":"Taiwan J. Obstet. Gynecol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00280-018-3686-5","article-title":"Safety of trifluridine\/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer","volume":"82","author":"Mayer","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1112224","DOI":"10.3389\/fonc.2023.1112224","article-title":"Case report: long-term survival in a patient with metastatic colorectal cancer treated with trifluridine\/tipiracil in the third-line setting","volume":"13","author":"Mohamed","year":"2023","journal-title":"Front. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00280-020-04129-6","article-title":"Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD\/TPI plus bevacizumab: a retrospective study","volume":"86","author":"Nose","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B22","unstructured":"Global cancer burden growing, amidst mounting need for services2024"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000533567","article-title":"Predicting trifluridine\/tipiracil treatment outcomes in refractory metastatic colorectal cancer patients: a multicenter exploratory analysis","volume":"102","author":"Prejac","year":"2024","journal-title":"Oncology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00228-014-1687-9","article-title":"Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups","volume":"70","author":"Qi","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1093\/oncolo\/oyae007","article-title":"Efficacy and safety of trifluridine\/tipiracil-containing combinations in colorectal cancer and other advanced solid tumors: a systematic review","volume":"29","author":"Shitara","year":"2024","journal-title":"Oncologist"},{"key":"B27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12885-022-10489-4","article-title":"Safety and efficacy of trifluridine\/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy","volume":"23","author":"Taieb","year":"2023","journal-title":"BMC Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"100633","DOI":"10.1016\/j.esmoop.2022.100633","article-title":"Pooled safety analysis from phase III studies of trifluridine\/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer","volume":"7","author":"Van Cutsem","year":"2022","journal-title":"ESMO Open"},{"key":"B29","doi-asserted-by":"publisher","first-page":"101477","DOI":"10.1016\/j.jgo.2023.101477","article-title":"Trifluridine\/tipiracil (FTD\/TPI) and regorafenib in older patients with metastatic colorectal cancer","volume":"14","author":"Victorino","year":"2023","journal-title":"J. Geriatr. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1186\/s12885-023-11618-3","article-title":"Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias","volume":"23","author":"Watanabe","year":"2023","journal-title":"BMC Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/apt.16601","article-title":"Bevacizumab and gastrointestinal perforations: a review from the FDA adverse event reporting system (FAERS) database","volume":"54","author":"Wichelmann","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in asian patients with previously treated metastatic colorectal cancer: the TERRA study","volume":"36","author":"Xu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1007\/s10147-023-02389-9","article-title":"Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study","volume":"28","author":"Yoshida","year":"2023","journal-title":"Int. J. Clin. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.annonc.2019.10.005","article-title":"Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine\/tipiracil in the RECOURSE and J003 trials","volume":"31","author":"Yoshino","year":"2020","journal-title":"Ann. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.2217\/fon-2020-1278","article-title":"Italian results of the PRECONNECT study: safety and efficacy of trifluridine\/tipiracil in metastatic colorectal cancer","volume":"17","author":"Zaniboni","year":"2021","journal-title":"Future Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"Zou","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","article-title":"A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database","volume":"14","author":"Zou","year":"2023","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1399998\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T08:58:14Z","timestamp":1721725094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1399998\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":37,"alternative-id":["10.3389\/fphar.2024.1399998"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1399998","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"article-number":"1399998"}}